Refining management strategies for Lennox-Gastaut syndrome: Updated algorithms and practical approaches


Por: Auvin S, Arzimanoglou A, Falip M, Striano P and Cross JH

Publicada: 1 feb 2025 Ahead of Print: 1 dic 2024
Resumen:
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy (DEE) characterized by multiple types of drug-resistant seizures (which must include tonic seizures) with classical onset before 8 years (although some cases with later onset have also been described), abnormal electroencephalographic features, and cognitive and behavioral impairments. Management and treatment of LGS are challenging, due to associated comorbidities and the treatment resistance of seizures. A panel of five epileptologists reconvened to provide updated guidance and treatment algorithms for LGS, incorporating recent advancements in antiseizure medications (ASMs) and understanding of DEEs. The resulting consensus document is based on current evidence from clinical trials and clinical practice and the panel's expert opinion, focusing on new ASMs with novel mechanisms of action, such as highly purified cannabidiol and fenfluramine. For a patient presenting with newly diagnosed LGS or suspected LGS, the recommended first-line treatment continues to be valproate. If this is ineffective as monotherapy, adjunctive therapy with, firstly, lamotrigine and secondly, rufinamide, is recommended. If seizure control remains suboptimal, subsequent adjunctive ASM treatment options include (alphabetically) cannabidiol, clobazam, felbamate, fenfluramine, and topiramate, although evidence for these is more limited. Whenever possible, no more than two ASMs should be used together. Nonpharmacological treatment approaches should be used in conjunction with ASM therapy and include ketogenic diet therapies, vagus nerve stimulation, and corpus callosotomy. Patients with LGS that has evolved from another type of epilepsy who are not already being treated with valproate should be transitioned to valproate and then managed using the same algorithm as for newly diagnosed LGS. Older patients with established LGS should be reviewed at least annually by a suitably experienced neurologist. The revised guidance aims to improve seizure control and quality of life for patients with LGS through personalized, evidence-based treatment strategies while addressing the challenges of accurate diagnosis and management in a rapidly evolving therapeutic landscape.

Filiaciones:
Auvin S:
 INSERM NeuroDiderot, Université Paris Cité, Paris, France

 Pediatric Neurology Department, CRMR Epilepsies Rares, ERN EpiCare, APHP, Robert Debré University Hospital, Paris, France

 Institut Universitaire de France, (IUF), Paris, France

Arzimanoglou A:
 Epilepsy Unit, Child Neurology Department, Hospital San Juan de Déu, Coordinator of the ERN EpiCARE, Universitat de Barcelona, Barcelona, Spain

Falip M:
 Epilepsy Unit, Neurology Service, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain

Striano P:
 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy

 IRCCS 'G. Gaslini' Institute, ERN EpiCARE, Genoa, Italy

Cross JH:
 UCL NIHR BRC Great Ormond Street Institute of Child Health, London, UK
ISSN: 24709239





Epilepsia Open
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ, Estados Unidos America
Tipo de documento: Editorial Material
Volumen: 10 Número: 1
Páginas: 85-106
WOS Id: 001381023200001
ID de PubMed: 39700524
imagen gold

MÉTRICAS